Filing Flows › Comparisons › ATTO vs HUMA
Attovia Therapeutics vs Humacyte: ATTO and HUMA compared
Attovia Therapeutics is the larger company: $450K of revenue in its latest quarter (Q2 2026) against $406K for Humacyte (Q2 2026).
Where the money goes: ATTO and HUMA
Attovia Therapeutics (ATTO) · Q2 2026
Attovia Therapeutics, Q2 2026: revenue $450K, net loss $20.7M. The chart follows the revenue to costs, profit and cash.
Humacyte (HUMA) · Q2 2026
Humacyte, Q2 2026: revenue $406K (+35% year over year), net loss $36.8M, operating cash flow −$22.1M. The chart follows the revenue to costs, profit and cash.
| Attovia Therapeutics (ATTO) | Humacyte (HUMA) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $450K | $406K |
| Revenue growth, Y/Y | — | +35% |
| Operating margin | n/m | n/m |
| Net earnings | −$20.7M | −$36.8M |
| Operating cash flow | — | −$22.1M |
Questions
Which is bigger, Attovia Therapeutics or Humacyte?
Attovia Therapeutics is the larger company: $450K of revenue in its latest quarter (Q2 2026) against $406K for Humacyte (Q2 2026).
More: Attovia Therapeutics earnings · how Attovia Therapeutics makes money · Humacyte earnings · how Humacyte makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Sep 2, 2026; 10-Q filed Aug 12, 2026). Fiscal quarters can end on different dates. Not investment advice.